IONS Stock Overview
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ionis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.92 |
| 52 Week High | US$54.44 |
| 52 Week Low | US$35.95 |
| Beta | 0.40 |
| 11 Month Change | -7.53% |
| 3 Month Change | 25.86% |
| 1 Year Change | 16.37% |
| 33 Year Change | 18.40% |
| 5 Year Change | -25.77% |
| Change since IPO | 369.20% |
Recent News & Updates
There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding
Aug 24
Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
Aug 11Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?
Jul 28Recent updates
There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding
Aug 24Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
Aug 11Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?
Jul 28Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
May 28Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report
May 09Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
Apr 14Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Feb 23Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected
Dec 28Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Nov 16Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals Looks Good For The Long Term
Oct 19Ionis plans for new manufacturing site in California to support pipeline
Oct 13Ionis: 2 Drug Advancements With Potential Firsts
Aug 29Ionis Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt
Aug 08Ionis Pharma: Too Many Programs Have Failed To Produce Confidence
Jun 15Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?
Apr 06Shareholder Returns
| IONS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.0% | 2.9% | 1.6% |
| 1Y | 16.4% | 16.0% | 26.4% |
Return vs Industry: IONS exceeded the US Biotechs industry which returned 14.8% over the past year.
Return vs Market: IONS underperformed the US Market which returned 25.3% over the past year.
Price Volatility
| IONS volatility | |
|---|---|
| IONS Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: IONS has not had significant price volatility in the past 3 months.
Volatility Over Time: IONS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 927 | Brett Monia | www.ionispharma.com |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.
Ionis Pharmaceuticals, Inc. Fundamentals Summary
| IONS fundamental statistics | |
|---|---|
| Market cap | US$6.95b |
| Earnings (TTM) | -US$365.74m |
| Revenue (TTM) | US$813.46m |
8.4x
P/S Ratio-18.8x
P/E RatioIs IONS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IONS income statement (TTM) | |
|---|---|
| Revenue | US$813.46m |
| Cost of Revenue | US$918.07m |
| Gross Profit | -US$104.61m |
| Other Expenses | US$261.13m |
| Earnings | -US$365.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.50 |
| Gross Margin | -12.86% |
| Net Profit Margin | -44.96% |
| Debt/Equity Ratio | 689.9% |
How did IONS perform over the long term?
See historical performance and comparison